2',3' -dideoxyribosides (i.e. azidothymidine, dideoxycytidine, didehydro-dideoxythymidine, fluorodideoxychlorouridine), in a subsynergistic manner, and the anti-HIV-1 activity of purine 2',3' -dideoxyribosides (dideoxyadenosine, dideoxyinosine, 2,6-diaminopurine dideoxyriboside) and 9-(2-phosphonylmethoxyethyl)adenine in a synergistic manner. Following intravenous administration of the sulphated cyclodextrins to rabbits, drug serum concentrations were obtained that were 100-to 1000-fold above the minimum inhibitory concentration for HIV or CMV.
Introduction
Sulphated polysaccharides, such as heparin, dextran sulphate, mannan sulphate and pentosan polysulphate, and sulphated polymers, such as polyvinylalcohol sulphate (PVAS) and co-polymers thereof with acrylic acid (PAVAS), are highly potent inhibitors of the replication of human immunodeficiency virus (HIV) in vitro (Ueno and Kuno, 1987; Saba et al., 1988a,b,c; Mitsuya et al., 1988; Ito et al., 1989; Nakashima et al., 1989) . Their mechanism of action has been attributed to an inhibition of virus adsorption to the cell membrane (Saba et al., 1988a,b,c; Mitsuya et al., 1988; Schols et al., 1989a) . We have now evaluated a series of SUlphated cyclic oligosaccharides (cyclodextrins) containing six (o-cyclcdextrln), seven (13-cyclodextrin) or eight (-y-cyclodextrin) glucopyranose units for their activity against a wide variety of DNA and RNA viruses. The compounds proved inhibitory to HIV, and also cytomegalovirus (CMV)and herpes simplex virus (HSV) . As demonstrated with HIV-1, the sulphated cyclodextrins interfere with the virus adsorption process.
We also examined 13-cyclodextrin tetradecasulphate for its anti-HIV-1 activity following combination with various nucleoside analogues, including pyrimidine and purine 2',3'-dideoxyribosides. Anand et al. (1990) recently reported that azidothymidine (AZ1) and cr-cyclodextrin sulphate may act in a synergistic fashion. Serum levels of the compounds were determined following their intravenous administration in rabbits, as based on an anti-HIV-2 bioassay that was specifically developed for this purpose.
Results

Anti-HIVactivity
When the sulphated cyclodextrins were evaluated for their inhibitory action on the cytopathic effect of HIV~1 in MT-4 cells, the n-, 13-and 'Y-cyclodextrins containing two sulphate groups per glucose unit were more active than the corresponding cyclodextrins containing only 1 sulphate group. Also, the anti-HIV-1 activity of the sulphated cyclodextrins depended on the number of glucopyranose units, sulphated 'Y-cyclodextrin (8 units) being more active than sulphated 13-cyclodextrin (7 units), which in turn was more active than sulphated o-cyclodextrin (6 units) (Table 1) .
With respect to HIV-2 activity, there was no direct correlation with the number of glucopyranose units, although the sulphated cyclodextrins with two sulphate groups per glucose unit were somewhat more active than those containing only 1 sulphate group per glucose unit (Table 1) . The anti-HIV-1 activity of the sulphated 13-and 'Y-cyclodextrin sulphate was more active than the sulphated cyclodextrins against HIV-2 (Table 1) . None of the test compounds proved toxic to mock-infected MT-4 cells at a concentration up to 2.5mg ml" (Table 1) . according to the following formula: IIvB= 1 -(MFvc -MFcc)/(MFv -MFc), whereby MFvc is the mean fluorescence (MF) with a given concentration of the compound in HIV-1-inoculated cells, MF cc is the mean fluorescence forthe control cells (not exposed to HIV-1)treated with compound, MF v is the mean fluorescence for the HIV-1-inoculated cells (not treated with any compound), and MFc is the mean fluorescence for the control cells (not exposed to HIV-1 and not treated with any compound). If II vB = 1, there is total inhibition of virus binding; if IIvB = 0, there is no inhibition of virus binding. All compounds were evaluated at a concentration of 25 [1g mr'.
All data represent mean values for at least three separate experiments.
I
The sulphated cyclodextrins were unable to inhibit HIV-1-induced giant cell (syncytium) formation, even at a concentration up to 500 fLg mr'. In contrast, the sulphated cyclodextrins were markedly inhibitory to HIV-2-induced giant cell formation (10;0: approximately 1 fL9 ml": Table 1 ). When evaluated under the same conditions, dextran sulphate effected a 50% reduction in giant cell formation, whether induced by HIV-1 or HIV-2, at a concentration of 20-25 fL9 rnl" (Table 1) . We have previously demonstrated by a flow cytometric method (Schols et al., 1989a) that dextran sulphate blocks HIV-1 binding to MT-4 cells. This finding apparently extends to the sulphated cyclodextrins which, like dextran sulphate, were also found to suppress HIV-1 binding to the cells (Table 1) . At 25 fL9 rnr", dextran sulphate almost completely blocked HIV-1 binding to the cells (II vB = 0.95). At 25 fL9 mr', the SUlphated cyclodextrins also achieved a marked inhibitory effect on virus binding: cyclodextrins containing two sulphate groups per glucose unit were more potent than cyclodextrins containing 1 sulphate group per glucose unit, and the longer the chain length the greater the inhibitory effect of the cyclodextrins on viruscell binding (Table 1) .
Activity against RNA viruses other than HIV
None of the sulphated cyclodextrins was active against poliovirus, Coxsackie B4 virus, Sindbis virus, Semliki Forest virus, influenza virus A, measles virus, parainfluenza virus type 3, respiratory syncytial virus, Junin virus, Tacaribe virus, vesicular stomatitis virus or reovirus type 1 (data not shown). When tested in parallel, dextran sulphate was active against Sindbis virus, respiratory syncytial virus, Junin virus, Tacaribe virus and vesicular stomatitis virus at a concentration of (IC 50 ) 20, 50, 20, 20 and 11 fLg mr ", respectively (data not shown; Schols et al., 1990c) .
Activity against DNA viruses
When the sulphated cyclodextrins were examined for their inhibitory effects on the replication of DNA viruses, they proved inhibitory to the herpesviruses HSV-1, HSV-2, TK-HSV-1 and, in particular, CMV (Table 2 ). However, their IC 5 0 for HSV and CMV was 1Q-100-fold higher than the IC 50 of dextran SUlphate, when evaluated under the same conditions. None of the sulphated cyclodextrins was inhibitory to vaccinia virus ( Table 2) . As a rule, sulphated I Sulphated cyclodextrins as anti-HIV agents 47
, cyciodextrins with two sulphate groups per glucose unit were more active than sulphated cyciodextrins with 1 sulphate group per glucose unit, and this difference was particularly striking for the AD-169 strain of eMV.
Combined antiviral effects
When f3-cyclodextrin tetradecasulphate was combined with AZT ( Fig. 1a ) and their inhibitory action on the cytopathic effect of HIV-1 was evaluated by the lsobologram method, the Fie (f3-cyclodextrin tetradecasulphate) + Fie (AZl) values fell between 0.5 and 1.0, which means that the combination was subsynergistic in its anti-HIV-1 activity. The minimum Fie index recorded for the combination of f3-cyclodextrin tetradecasulphate and AZT was 0.6. When -y-cyclodextrin octasulphate and -y-cyclodextrin hexadecasulphate were administered intravenously to rabbits at a dose of 0.1 g kg-1 , compound concentrations in the serum at 20min after injection were 1.2 mg mr' and 0.9mg rnl", respectively (Fig. 2) . The serum concentration obtained for dextran sulphate when evaluated under similar conditions was 0.5 mg rnl" (Witvrouw et al., 1990) .
The serum concentrations of v-cyclodextrln octasulphate and v-cyclodextrin hexadecasulphate declined biphasi-cally with an initial half-life of 35min and 20min, respectively.
Discussion
Our studies have indicated that sulphated cyclodextrins protect the cells against the cytopathic effect of both HIV-1 and HIV-2. In this respect they behave similarly to dextran sulphate. However, the sulphated cyclodextrins differ markedly from dextran sulphate ( While not effective against HIV-1-induced syncytium formation, the sulphated cyclodextrins are remarkably effective in suppressing HIV-2-induced syncytium formation. Sulphated polysaccharides are known to interact with the V3 region of the viral envelope gp120 glycoprotein (Schols et al., 1990a) and this may explain why they inhibit fusion (syncytium formation) of HIV-infected cells with uninfected GD4+ cells. The fact that the sulphated cyclodextrins inhibit HIV-2-induced, but not HIV-1induced syncytium formation suggests that there exist marked differences in those parts of the HIV-1 and HIV-2 gp120 glycoproteins that are involved in fusion.
Little is known about the HIV-2 glycoproteins, and monoclonal antibodies towards HIV-2 glycoproteins that may be useful to decipher to which portions of the HIV-2 gp120 the sulphated cyclodextrins interact are not (yet) available. Sulphated cyclodextrins inhibit binding of the HIV particles to the cells (Table 1) , and thus behave similarly to other sulphated polysaccharides (Baba et al., 1988b; Mitsuya et al., 1988) and sulphated polymers Schols et al., 1990c) , which also inhibit HIV binding to the cells. Although there is a direct correlation between the inhibition of virus binding to the cells and the antiviral effect of the sulphated cyclodextrins (Table 1) , it cannot be ruled out that the compounds not only inhibit virus binding but also interact with a post-binding event (i.e. fusion) (Anand et aI., 1990) .
The pyrimidine 2',3'-dideoxyribosides AZT, ddG, D4T and FddGIUrd showed a subsynergistic effect, whereas • 1.5 2 2.5 3 3.5 Time (h) Other drug combinations examined for their inhibitory action on the cytopathic effect of HIV-1 were combinations of l3-cyclodextrin tetradecasulphate with ddG ( Fig.  1b) , d4T (Fig. 1c) , FddGIUrd (Fig. 1d) , ddA (Fig. 1e) , ddl ( Fig. 1f) , ddDAPR (Fig. 1g) or PMEA (Fig. 1h) . When l3-cyclodextrin tetradecasulphate was combined with ddG, D4T or FddGIUrd, the minimum FIG indexes comprised between 0.5 and 1.0, indicating a subsynergistic effect of these combinations. When l3-cyclodextrin tetradecasulphate was combined with ddA, ddl, ddDAPR or PMEA, the minimum FIG indexes approached or even fell below the 0.5 level, indicating a synergistic action for these combinations (Fig. 1e-h) . No reduction in viability of the MT-4 cells was observed with any of the combinations used (data not shown). the purine nucleoside analogues ddA, ddl, ddDAPR and PMEA acted rather synergistically with (3-cyclodextrin sulphate. All these compounds have been shown previously to inhibit HIV replication in vitro (Cooney et al., 1986; Yarchoan etal., 1986; Balzarini etal., 1987 Balzarini etal., , 1988 Balzarini etal., , 1989a Nakashima et al., 1987; De Clercq et al., 1988; . Various other drugs, i.e. dextran sulphate (Ueno and Kuno, 1987) , soluble CD4 (Johnson et al., 1989a) , castanospermine (Johnson et al., 1989b) , PMEA (Smith et al., 1989) , phosphonoformate (Eriksson and, Schinazi, 1989) , alpha A interferon (Hartshorn et al., 1987) and alpha-cyclodextrin sulphate (Anand et al., 1990) have been reported previously to act synergistically with AZT. From our findings (Fig. 1) it appears that the purine nucleoside analogues are more prone to a synergistic action with the sulphated (3-cyclodextrin than the pyrimidine nucleoside analogues. This synergistic action may result from the capturing of the nucleoside analogues within the central cavity of the cyclodextrins, and the higher synergistic activity achieved by the purine nucleoside analogues may suggest that they are captured more easily than the pyrimidine nucleoside analogues. It is noteworthy in this regard that a very high anti-angiogenic activity was achieved with the combination of (3-cyclodextrln tetradecasulphate and certain steroids (Folkman et el., 1989) . The sulphated cyclodextrins are not only inhibitory to HIVbut also CMV replication (Table2).This increasestheir therapeutic potential for the treatment of AIDS patients, where CMV infections are the most frequent cause of death (Reichert et el., 1983) . Further attesting to the therapeutic potential of the sulphated cyclodextrins is that following intravenous administration to rabbits, serum drug concentrations were obtained that were 100-1000fold greater than the minimum inhibitory concentrations required for suppressing HIV or CMV infection in vitro. Our findings also indicate that ddl combined with (3-cyclodextrin tetradecasulphate causes a synergistic anti-HIV activity without concomitant increase in toxicity. Since ddl has been shown to suppress HIV-1 replication in patients with AIDS and AIDS related complex (Yarchoan et el., 1989) , a combination with a sulphate cyclodextrin may represent an interesting therapeutic approach towards the treatment of AIDS patients.
Materials and Experimental procedures
Compounds
The u-, [3-and v-cyclodextrins are naturally occurring, cyclic, non-reducing, water-soluble oligosaccharides containing six, seven or eight glucopyranose units, respectively. The glycosidic bridges point to the centre of the molecule, thus producing a hydrophobic cavity. The free hydroxyl groups are situated on the outer surface of the ring, which consequently has a relatively Sulphated cyclodextrins as anti-HIVagents 49 hydrophilic character (Fig. 3) . The cyclodextrins were obtained from Aldrich Chemical Co. (Brussels, Belgium). Dextran sulphate (5000: MW) was purchased from Sigma Chemical Co. (St Louis, MO). 2',3'-Dideoxyadenosine (ddA), 2',3'-dideoxyinosine (ddl) and 2',3'-dideoxycytidine (ddC) were obtained from Pharmacia PL-Biochemicals (Piscataway, NJ). 3' -Azido-2' ,3' -dideoxythymidine (AZ1), 2',3'-didehydro-2',3'-dideoxythymidine (D41), 2',3'dideoxy-2,6-diaminopurine riboside (ddDAPR), 3'-fluoro-2' ,3'dideoxy-5-chlorouridine (FddCIUrd) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) were synthesized in our Institute as described previously Van Aerschot et al., 1989) .
Chemistry of the sulphated cyclodextrins
The a-, [3-and 'Y-cyclodextrins were sulphated with the sulphur trioxide trimethylamine complex in dimethylformamide using a procedure similar to that reported by Folkman et al., (1989) .
The precipitate obtained upon treatment of a 4% a-cyclodextrin solution in dimethylformamide at 70°C appeared to be hexasulphate trimethylammonium salt, with the sulphate groups on the less-hindered hydroxyls in the 6-position. [3-Cyclodextrin heptasulphate and 'Y-cyclodextrin octasulphate were prepared in a similar way. These sulphated cyclodextrins thus contain approximately one sulphate group per glucose unit.
When the sulphatation of a-cyclodextrin was conducted at 110°C under more dilute reaction conditions, the hexasulphate remained in solution and could be converted to the dodecasulphate. The same reaction conditions were also used for the preparation of the [3-cyclodextrin tetradecasulphate and the -y-cyclodextrin hexadecasulphate, and these sulphated cyclodextrins thus contain approximately two sulphate groups per glucose unit.
The sulphates were isolated as their sodium salts and purified (freed from mineral salts) on a Sephadex G-15 column. The degree of sulphation, e.g. the number of sulphate groups per glucose unit, of all cyclodextrin derivatives was determined by titration of the amount of free-acid obtained by passage of the sodium salt over an AG 50W-X8 ion-exchange resin in the H+ form. The results thus obtained for the cyclodextrins sulphated at 110°C were as follows: 2.1 for a-cyclodextrin (2259: MW), 1.9 for [3-cyclodextrin (2492: MW), and 2.2 for v-cyclodextrin (3093: MW). These results are in agreement with the sulphur content obtained by elemental analysis: e.g. the calculated sulphur content of a-cyclodextrin dodecasulphate was 18.29%, as compared to 18.40% determined by elemental analysis. Titrations of the cyclodextrins that were sulphated at 70°C gave the following degrees of sulphatation: 1.2 for o-cyclodextrln (1708: MW), 1.3 for [3-cyclodextrin (2064: MW), and 1.2 for v-cyclodextrin (2277: MW). The sulphur content was somewhat higher than the calculated percentage, which points to the formation of some 2,3-cyclic sulphates, which could not be detected by titration. These cyclodextrin sulphates did not have reducing properties, which indicates that the cyclic oligosaccharide structure had remained intact.
a-Cyclodextrin hexasulphate (Na-salt)
Sulphur trioxide trimethylamine complex (13.90g, 8.1 equiv./ glucose unit) was added to a stirred solution of «-cyclodextrln (2.0g, 2.06mmol) in 50ml anhydrous dimethylformamide and (0) heated at 70°C for 24h. The reaction mixture was cooled and the precipitate was dissolved in 160ml of a 6% aqueous NaOAc solution. The crude o-cyclodextrln sulphate was precipitated by addition of 160ml EtOH, the precipitate filtered off and washed twice with EtOH. Mineral salts were removed by chromatography on a 3.5 x 40cm Sephadex G-15 column. The effluent was monitored by TLC using a silica gel plate and a mixture of MeOH-n-PrOH-H 20-33% NH 3-10% CCI 3COOH (50:30:15:8:1.5) (Seiler and Seiler, 1965) as the mobile phase. Cyclodextrin sulphate was visualized with the naphtoresorcinol reagent and mineral salts with bromocresol green. Fractions containing pure cyclodextrin sulphate were concentrated and freeze-dried. The solid material was dried in vacuoover P 20S , yielding 2.87 g (88%) of the title compound, which showed a negative test with the aniline phthalate reagent (Peschke, 1965) for reducing sugars.
a-Cyclodextrin dodecasulphate (Na-salt)
o-Cyclodextrln (2.23g, 2.29mmol) was reacted with sulphur trioxide trimethylamine complex (15.50g, 8.1 equiv.lglucose unit) in dimethylformamide (125ml) for 24 h at 110°C. The reaction mixture was worked up as described in the previous section, affording 4.20g (83% yield) of the title compound.
Determination of the degree of sulphation
The degree of sulphatation (expressed as the number of sulphate groups per glucose unit) was determined by passing an aliquot (100mg) of the cyclodextrin sulphate through a 7 ml AG 50W-X8 column in the H+ form. The free acid was eluted with water, quantitatively collected and titrated with 0.1 N NaOH.
Viruses
The virus stocks were prepared as described previously: herpes simplex virus type 1 (HSV-1) (strain KOS), HSV-2 (strain G), the thymidine kinase-deficient (TK-) mutant of HSV-1 (B2006 strain) and vaccinia virus (DeClercq et al., 1980) ; HIV-1 (strain HTLV-lIl s) (Popovic et al., 1984) ; HIV-2 (strain UW-2ROO) (Bam3- Sinoussi et al., 1983) ; CMV [strain Davis (ATCC VR-807) and strain AD-169 (ATCC VR-538), American Type Culture Collection (Rockville, MD)]. HIV-1 and HIV-2 were prepared from the supernatant of HUT-78/HTLV-lIl s and HUT-78/LAV-2 Ro o cells, i.e, HUT-78 cells persistently infected with HTLV-Ill s or LAV-2 RO O , respectively.
Antiviral assays
For HSV and vaccinia virus, confluent cell cultures EeSM (human fibroblasts) in microtitre trays were inoculated with virus at 100 CCID so (50% cell culture infective dose) per well in the presence of various concentrations of the test compounds. After a 1-h adsorption period at 3rC, residual virus was replaced by culture medium [Eagle's minimum essential medium (MEM) supplemented with 3% foetal calf serum (FCS)and antibiotics] containing the test compounds at the same concentrations as during the virus adsorption period.
For the anti-CMV assays, human embryonic lung (HEL) fibroblasts were grown in MEM supplemented with 10% inactivated FCS, 1% L-glutamine and 0.3% sodium bicarbonate. Thecells were infected with 20 PFU (plaque-forming units) of virus. Compounds and virus were added at the same time, and the cells were further incubated at 37°C in MEM supplemented with 2% FCS. Virus plaque formation was monitored as described previously (Snoeck et al., 1988) .
The inhibitory effects of the compounds on HIV-1 and HIV-2 replication were assessed by the inhibition of virus-induced cytopathic effect in MT-4 cells (Miyoshi et aI., 1982) , monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, described previously (Pauwels et aI., 1988a) .
Virus-induced cytopathic effect was recorded at 2-3 days for HSV-1, HSV-2, TK-HSV-1 and vaccinia virus, at 5 days for HIV-1 and HIV-2. and at 6 to 7 days for CMV.
Giant cell formation assay
MOLT-4 cells (5 x 10 5 ) were co-cultured with an equal number of HUT-78/HTLV-lll s or HUT-78/LAV-2 Ro D cells in microtitre tray wells containing various concentrations of the test compounds. After 24h co-cultivation, cells were analysed by laser flow cytofluorography, as described previously (Schols et aI., 1989b (Schols et aI., , 1990b . "
Virus adsorption assay
The inhibitory effects of the test compounds on virus adsorption were measured by an indirect immunofluorescence-laser flow cytofluorographic method specifically designed for this purpose (Schols et al., 1989a) . MT-4 cells were exposed to HIV-1 virions, which had been concentrated from the supernatant of HUT-781 HTLV-lII s cells in the presence or absence ofthe test compounds. The compounds were added 1D-20seconds before virus was added. The cells were incubated for 30min at 37"C and washed twice in phosphate-buffered saline (PBS) to remove unbound virus. Then a high-titre polyclonal antibody derived from a patient with AIDS-related complex (diluted 1/500 in PBS) was added. After another ·30min incubation at room temperature, the cells were washed twice with PBS. The cells were then incubated with fluorescein isothiocyanate conjugated F(ab'h fragments of rabbit anti-human immunoglobulin antibody (diluted 1/30 in PBS) for 30min at room temperature, washed once in PBS, resuspended in 0.5 ml of 0.5% paraformaldehyde in PBS, and analysed by laser flow cytofluorography.
Bioassay
Serum concentrations of the compounds (following intravenous administration to rabbits) were determined by a bioassay, as described by Witvrouw et al. (1990) . Four rabbits received an intravenous injection (inthe ear vein) of the sulphated cyclodextrin (two with 'Y-cyclodextrin octasulphate and two with 'Y-cyclodex-
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trin hexadecasulphate) at a dose of 0.1 g kg-1 . At different times after injection, the blood was collected from the contralateral ear and kept at 4°C for a period of 12h, after which the serum was collected. The samples were stored at -20°C until assayed. The compound concentrations in the serum were determined by measuring the inhibitory effect of the serum samples on the HIV-2-induced cytopathic effect in MT-4 cells.
